S&P 500

5.460,61

-0,16%

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

Startseite
Investieren
Aktien
USA
NASDAQ
New River Pharmaceuticals (MM) (NRPH)
New River Pharmaceuticals (MM) (NRPH) News

NRPH

New River (NRPH)

New River Pharmaceuticals (MM)

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NRPH

1 2 3 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
18/04/2007	22h41	PR Newswire (US)	HealthShares(TM) Announces Changes to the HealthShares(TM) Neuroscience and Composite Indices	NASDAQ:NRPH	New River Pharmaceuticals (MM)
03/04/2007	15h00	PR Newswire (US)	New River Pharmaceuticals Inc. Announces Convertibility of 3.50% Convertible Subordinated Notes Due 2013	NASDAQ:NRPH	New River Pharmaceuticals (MM)
19/03/2007	15h00	PR Newswire (US)	New River Announces Expiration of Hart-Scott-Rodino Waiting Period	NASDAQ:NRPH	New River Pharmaceuticals (MM)
14/03/2007	00h30	PR Newswire (US)	New River Pharmaceuticals Announces Year-End Results	NASDAQ:NRPH	New River Pharmaceuticals (MM)
23/02/2007	23h07	PR Newswire (US)	Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSE(TM) (lisdexamfetamine	NASDAQ:NRPH	New River Pharmaceuticals (MM)
20/02/2007	12h00	PR Newswire (US)	New River Pharmaceuticals to be Acquired by Shire plc for $64 per Share	NASDAQ:NRPH	New River Pharmaceuticals (MM)
05/02/2007	16h18	PR Newswire (US)	New River Pharmaceuticals to Present at 2007 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Conference	NASDAQ:NRPH	New River Pharmaceuticals (MM)
25/01/2007	21h01	PR Newswire (US)	James Shaffer Joins New River Pharmaceuticals as Vice President, Sales and Marketing	NASDAQ:NRPH	New River Pharmaceuticals (MM)
22/12/2006	05h34	PR Newswire (US)	New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of	NASDAQ:NRPH	New River Pharmaceuticals (MM)
22/12/2006	05h34	PR Newswire (US)	New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of	NASDAQ:NRPH	New River Pharmaceuticals (MM)
07/11/2006	23h22	PR Newswire (US)	New River Pharmaceuticals Announces Third Quarter 2006 Results	NASDAQ:NRPH	New River Pharmaceuticals (MM)
30/10/2006	15h00	PR Newswire (US)	Interim Results of a Phase III Trial of Lisdexamfetamine Dimesylate (NRP104/LDX) in ADHD Presented at Major Scientific Meeting	NASDAQ:NRPH	New River Pharmaceuticals (MM)
13/10/2006	15h45	PR Newswire (US)	New River Pharmaceuticals Conducts End-of-Phase II Meeting with FDA for NRP290	NASDAQ:NRPH	New River Pharmaceuticals (MM)
07/10/2006	03h25	PR Newswire (US)	FDA Issues Approvable Letter for NRP104 (lisdexamfetamine dimesylate) for the Treatment of ADHD	NASDAQ:NRPH	New River Pharmaceuticals (MM)
07/10/2006	03h23	PR Newswire (US)	New River Pharmaceuticals Inc. Receives Approvable Letter for NRP104	NASDAQ:NRPH	New River Pharmaceuticals (MM)
03/10/2006	23h20	PR Newswire (US)	Dr. Garen Manvelian Joins New River Pharmaceuticals as Chief Medical Officer	NASDAQ:NRPH	New River Pharmaceuticals (MM)
12/09/2006	21h00	PR Newswire (US)	New River Pharmaceuticals Inc. Meets Enrollment in NRP104 Adult Phase III Study	NASDAQ:NRPH	New River Pharmaceuticals (MM)
08/09/2006	23h38	PR Newswire (US)	New River Pharmaceuticals to Present at the Bear Stearns 19th Annual Healthcare Conference	NASDAQ:NRPH	New River Pharmaceuticals (MM)
18/08/2006	00h03	PR Newswire (US)	New River Pharmaceuticals Names Dr. Samir Roy Vice President, Formulation and Manufacturing	NASDAQ:NRPH	New River Pharmaceuticals (MM)
08/08/2006	23h46	PR Newswire (US)	New River Pharmaceuticals Announces Second Quarter 2006 Results	NASDAQ:NRPH	New River Pharmaceuticals (MM)
25/07/2006	22h58	PR Newswire (US)	New River Pharmaceuticals Announces Exercise of Co-Promotion Option in the U.S. for NRP104	NASDAQ:NRPH	New River Pharmaceuticals (MM)
25/07/2006	18h57	PR Newswire (US)	New River Pharmaceuticals Closes Sale of $135,000,000 Convertible Subordinated Notes	NASDAQ:NRPH	New River Pharmaceuticals (MM)
24/07/2006	15h41	Business Wire	AMRI Announces Long-Term Manufacturing Agreement with New River Pharmaceuticals	NASDAQ:NRPH	New River Pharmaceuticals (MM)
20/07/2006	03h06	PR Newswire (US)	New River Pharmaceuticals Prices $125 Million Convertible Subordinated Notes; Company to Repurchase Up to $51 million in Common	NASDAQ:NRPH	New River Pharmaceuticals (MM)
18/07/2006	23h26	PR Newswire (US)	New River Pharmaceuticals Announces Proposal to Offer $125 Million Convertible Subordinated Notes; Company to Repurchase up to	NASDAQ:NRPH	New River Pharmaceuticals (MM)
30/06/2006	16h31	PR Newswire (US)	New River Pharmaceuticals Announces Filing of Investigational New Drug Application for NRP409	NASDAQ:NRPH	New River Pharmaceuticals (MM)
23/06/2006	18h52	PR Newswire (US)	New River Pharmaceuticals to Host Conference Call on A01, A02 and A03 Clinical Abuse Liability Studies of NRP104	NASDAQ:NRPH	New River Pharmaceuticals (MM)
20/06/2006	23h30	PR Newswire (US)	New River Pharmaceuticals Provides Detail on A02 Clinical Abuse Liability Study of NRP104	NASDAQ:NRPH	New River Pharmaceuticals (MM)
18/06/2006	23h45	PR Newswire (US)	New River Pharmaceuticals Provides Detail on A01 Clinical Abuse Liability Study and Announces Results from A03 Study	NASDAQ:NRPH	New River Pharmaceuticals (MM)
14/06/2006	15h01	PR Newswire (US)	New River Pharmaceuticals to Present Results from NRP104 Abuse Liability Studies	NASDAQ:NRPH	New River Pharmaceuticals (MM)